Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05305911 · ClinicalTrials.gov registry record · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
A Phase 2 study of Heart Attack and Enlarged Heart, sponsored by Minneapolis Heart Institute Foundation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
- 1
- Study location
NCT05305911 is a Phase 2 study of Heart Attack and Enlarged Heart that is actively recruiting participants, run by Minneapolis Heart Institute Foundation. The registered enrollment target is 81 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05305911, a Phase 2 study of Heart Attack and Enlarged Heart, is actively recruiting participants, sponsored by Minneapolis Heart Institute Foundation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking this class of medication (or a placebo) once daily for six months, one cardiac magnetic resonance imaging (MRI) test during your initial hospitalization, follow-up phone calls at 1 and 3 months, and one cardiac MRI and clinic visit at six months. This is a single center study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SGLT-2 inhibitors
Study Locations (1)
Minnesota
- Minneapolis Heart Institute Foundation - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2022-08-03 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05305911
The ClinicalTrials.gov registry entry for NCT05305911 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Minneapolis Heart Institute Foundation, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Heart Attack appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05305911 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT05305911 about?
NCT05305911 is a clinical study titled "Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI". The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking this class of medication (or a placebo) once daily for six months, one c...
What is the current status of trial NCT05305911?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2022-08-03. Estimated completion is 2028-12.
What conditions does trial NCT05305911 study?
This clinical trial studies the following conditions: Heart Attack, Enlarged Heart.
What interventions are being tested in trial NCT05305911?
The interventions under investigation include: Placebo (DRUG), SGLT-2 inhibitors (DRUG).
Who is sponsoring clinical trial NCT05305911?
This trial is sponsored by Minneapolis Heart Institute Foundation, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05305911 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Attack
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.